The North America Laparoscopic Power Morcellators Market would witness market growth of 7.8% CAGR during the forecast period (2021-2027).
There is an increasing prevalence of uterine fibroids in women across the globe. This can cause abnormal uterine bleeding, amenorrhea, dysmenorrhea which is painful and heavy menstrual periods, and increased pelvic and abdominal pressure. It is predicted that more than 50 to 75% of cases remain asymptomatic which means there are no symptoms of uterine fibroids and often remain undiagnosed. Therefore, it is projected that approximately 77% of women who are under childbearing age have uterine fibroids.
According to a report published in the NCBI study, there are around 30,000 myomectomies that are performed annually for leiomyomata (fibroids) in the USA due to the occurrences of uterine fibroids increases with the increasing age of women. It may occur in more than 30% of women who are between 40 to 60 years of age. Furthermore, the U.S. National Institutes of Health, estimated that more than 793,846 women were diagnosed with uterine cancer in 2017. In addition to it, the new cases of uterine cancer are continuously increasing. This is promoting the growth of uterine fibroid treatment procedures including the laparoscopic power morcellators market. Thus, the increasing prevalence of uterine fibroids is leading to the massive demand for myomectomy or hysterectomy procedures across the globe. Thus, it is expected to boost the growth of the laparoscopic power morcellators market over the forecast period.
The demand for laparoscopic power morcellators is high in North America. It is due to increasing awareness programs about fibroid treatment by numerous organizations that, in turn, increasing the demand for fibroid treatment devices across the world. For example, In the U.S., July is now recognized as “Fibroid Awareness Month”. These programs are creating awareness about an extremely prevalent gynecological condition by which 8 out of 10 women above the age of 50 years are affected.
The increasing gynecological surgical procedures along with well-established healthcare infrastructure are the major factors leading to the growth of the laparoscopic power morcellators market in this region. Furthermore, increasing government initiatives, availability of advanced medical equipment and services, as well as the presence of an aware patient population are anticipated to increase the regional demand for laparoscopic power morcellators during the forecast period.
The US market dominated the North America Myomectomy Market by Country in 2020, and would continue to be a dominant market till 2027; growing at a CAGR of 6.3 % during the forecast period. The Canada market is experiencing a CAGR of 9.4% during (2021 - 2027). Additionally, The Mexico market would witness a CAGR of 8.5% during (2021 - 2027).
Based on Application, the market is segmented into Hysterectomy, Myomectomy and Other Applications. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Laparoscopic Power Morcellators Market is Estimated to Reach USD 176.2 Million by 2027 at a CAGR of 8.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Karl Storz SE & Co. KG, Cook Medical, Inc. (Cook Group), Olympus Corporation, Johnson and Johnson, Lina Medical, Nouvag AG, Rudolf Medical GmbH, OWA- Electronic GmbH & Co. KG, and Richard Wolf GmbH.
By Application
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 